dabigatran has been researched along with vitamin k semiquinone radical in 286 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (vitamin k semiquinone radical) | Trials (vitamin k semiquinone radical) | Recent Studies (post-2010) (vitamin k semiquinone radical) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 12,827 | 491 | 3,703 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (3.15) | 29.6817 |
| 2010's | 207 (72.38) | 24.3611 |
| 2020's | 70 (24.48) | 2.80 |
| Authors | Studies |
|---|---|
| Gustafsson, D | 1 |
| Haas, S; Schellong, S | 1 |
| Bode, Ch; Schwarz, M | 1 |
| Bounameaux, H | 1 |
| Arnaout, L; Bellamy, L; Rosencher, N | 1 |
| Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M | 1 |
| Thorsten, L | 1 |
| Einecke, D | 1 |
| Laufs, U; Röther, J | 1 |
| Malaga, G; Malasquez, G; Salazar, CA | 1 |
| Díaz-Cremades, JM; Fernández-Fuertes, F; Ruano, JA | 1 |
| Ahrens, I; Lip, GY; Peter, K | 1 |
| Alban, S; Völler, H; Westermann, D | 1 |
| Ageno, W; Rancan, E; Romualdi, E; Siragusa, S | 1 |
| Broukhim, M; Halperin, JL | 1 |
| Gil Núñez, A | 2 |
| Heidbuchel, H; Verhamme, P | 1 |
| Aikens, TH; Chernick, MR; Connolly, SJ; Ezekowitz, MD; Lip, GY; Parekh, A; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Weitz, JI | 1 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Calvo Romero, JM | 1 |
| Eikelboom, JW; Haroun, MJ; Paikin, JS | 1 |
| Guay, DR | 1 |
| Nutescu, E | 1 |
| Gawaz, M; Geisler, T | 1 |
| Stiefelhagen, P | 1 |
| Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
| Augoustides, JG | 1 |
| Heidinger, K; Kemkes-Matthes, B | 1 |
| Garwood, CL; Hwang, JM; Moser, LR | 1 |
| Finsterer, J; Stöllberger, C | 1 |
| Diener, HC; Hohnloser, SH; Lip, GY; Weber, R | 1 |
| Ageno, W; Crowther, M; Gallus, AS; Hylek, EM; Palareti, G; Wittkowsky, A | 1 |
| Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Palareti, G; Tripodi, A | 1 |
| Brouns, R; De Keyser, J; De Raedt, S; De Smedt, A; Jochmans, K; Luijckx, GJ; Moens, M; Uyttenboogaart, M; Van Hooff, RJ | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| Ataullakhanov, FI; Panteleev, MA; Sinauridze, EI | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Ansell, J; Mantha, S | 1 |
| Alonso-Coello, P; Guyatt, G; Zhou, Q | 1 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC | 1 |
| Le Heuzey, JY | 1 |
| Haschke, M | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Ortel, TL | 1 |
| Eichler, K; Plessow, R; Pletscher, M; Wieser, S | 1 |
| Grove, EL; Husted, SE; Kraglund, KL; Modrau, B | 1 |
| Buch, TN; Holm, J; Munck, LK | 1 |
| Bock, F; Hartung, K; Isermann, B; Meyer, F | 1 |
| Dolgin, E | 1 |
| Dalla Valle, F; Pesavento, R; Piovella, C; Prandoni, P; Tormene, D | 1 |
| Baumann, MR; Cabral, KP; Croft, PE; Delaney, MC; Gibbs, MA; Strout, TD | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Darius, H; Sommer, S | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Bauer, KA | 1 |
| Chana, F; Llau, JV; Marco, P; Zamorano, JL | 1 |
| Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L | 1 |
| Ansell, J; Shameem, R | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Braun, G; Messmann, H | 1 |
| Okada, Y; Yasaka, M | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Diener, HC; Weber, R | 1 |
| Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
| Hanon, O | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Acket, B; Bagheri, H; Bourrel, R; Lavezzi, O; Molinier, A; Montastruc, JL | 1 |
| Bassand, JP | 1 |
| Cordova, EG; del Aguila, D; Salazar, CA | 1 |
| Beyer-Westendorf, J; Ebertz, F; Förster, K; Gelbricht, V; Hänsel, U; Köhler, C; Kuhlisch, E; Röder, I; Röllig, D; Schreier, T; Stange, T; Thieme, C; Tittl, L; Weiss, N; Werth, S | 1 |
| Gislason, G; Sørensen, R | 1 |
| Alegret, JM; Arias, MA; Martínez-Rubio, A; Martínez-Sande, JL; Ràfols, C; Rebollo, P; Viñolas, X | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Hess, T; Konturek, P | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Barco, S; Coppens, M; Middeldorp, S; Stroobants, AK; van de Kerkhof, D; van den Dool, EJ | 1 |
| Akl, EA; Barba, M; Kahale, L; Labedi, N; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| Garg, P; Morris, P; Morris, PD; Saraf, K; Sheridan, P; Storey, R | 1 |
| Husted, SE; Thorup, SB; Vang, ML | 1 |
| Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J | 1 |
| Kovács, T | 1 |
| Ageno, W; Beyer-Westendorf, J | 1 |
| Beyer-Westendorf, J | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Du, S; Harenberg, J; Krämer, R; Krämer, S; Wehling, M; Weiss, C | 1 |
| Blann, AD | 1 |
| Bruckner, T; Hess, A; Katus, HA; Kieser, M; Mereles, D; Pohlmeier, M; Scholz, E; Schweizer, PA; Thomas, D; Zitron, E; Zylla, MM | 1 |
| Harel, Z; Perl, J; Sood, MM | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Hjemdahl, P; Mullier, F; Pohanka, A; Rönquist-Nii, Y; Sennesael, AL; Wallemacq, P | 1 |
| Greinacher, A; Selleng, K; Thiele, T | 1 |
| Blaich, C; Michels, G; Müller, C; Wiesen, MH | 1 |
| Amato, A; Dentali, F; Dumonceau, JM; Paggi, S; Radaelli, F; Repici, A; Rondonotti, E | 1 |
| Beyer-Westendorf, J; Breslin, T; NiAinle, F; Werth, S | 1 |
| Saliba, W | 1 |
| Fanola, CL | 1 |
| Crawford, B; Morimoto, T; Ueda, S; Wada, K | 1 |
| Alla, F; Billionnet, C; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Bolton-Maggs, PH; Shearer, MJ; Thachil, J; Walsh, V | 1 |
| Alonso-Coello, P; Brosa, M; Carles, M; Garcia-Alamino, JM; Guyatt, G; Souto, JC | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; Elsaesser, A; Halperin, JL; Huisman, MV; Lip, GY; Ma, C; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Aghi, A; Arcidiacono, MV; Dalle Carbonare, L; Dusso, A; Fusaro, M; Gallieni, M; Pasho, S; Valenti, MT | 1 |
| Beinema, MJ; Brouwers, JR; Jansman, FG; Postma, MJ; Stevanović, J; van Leent, MW | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Maron, B; Rossaint, R; Spronk, HM; ten Cate, H; van Ryn, J | 1 |
| Brueckmann, M; Clemens, A; Kreuzer, J; Liesenfeld, KH; Schulze, F | 1 |
| Riess, H | 1 |
| Crosca, S; Messina, F; Romano, P | 1 |
| Beney, J; Bochatay, L; Jordan-von Gunten, V; Petignat, PA; Roulet, L | 1 |
| Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM | 1 |
| Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H | 1 |
| Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Agewall, S; Atar, D; Drexel, H; Husted, SE; Kaski, JC; Kjeldsen, K; Koller, L; Lewis, BS; Lip, GYH; Morais, J; Niessner, A; Storey, RF; Tamargo, J; Torp-Pedersen, C; Verheugt, FWA; Wassmann, S | 1 |
| Al-Khalili, F; Benson, L; Lindström, C | 1 |
| Angoulvant, D; Babuty, D; Bejan-Angoulvant, T; Darwiche, W; Dievart, F; Fauchier, L | 1 |
| Shao, XH; Wan, HB; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Beyer-Westendorf, J; Ehlken, B; Evers, T | 1 |
| Ansell, JE | 1 |
| Alcocer, L | 1 |
| Aita, A; Angeli, F; Bartolini, C; Reboldi, G; Verdecchia, P | 1 |
| Feng, Y; Li, PJ; Liang, ZA; Liu, GJ; Wang, T; Xiao, J; Yang, Q | 1 |
| Majeed, A; Schulman, S; Shrum, J | 1 |
| Agnelli, G; Becattini, C; Cianella, F; Conti, S; Filippucci, E; Giustozzi, M; Marchesini, E; Pierpaoli, L; Vedovati, MC; Verdecchia, P; Verso, M | 1 |
| Carmo, J; Ferreira, J; Mendes, M; Moscoso Costa, F | 1 |
| Berger, K; Lesch, CA; Sin, JH | 1 |
| Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F | 1 |
| Gislason, GH; Lee, CJ; Lindhardt, TB; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Kawasugi, K; Kita, H; Kuyama, Y; Shirai, T; Yamamoto, T | 1 |
| Angoulvant, D; Babuty, D; Bejan-Angoulvant, T; Darwiche, W; Fauchier, L | 1 |
| Freedman, B; Lip, GY | 1 |
| Dyrkorn, R; Lundgaard, H; Molden, E; Spigset, O; Stokes, CL | 1 |
| Bonde, AN; Fosbøl, EL; Gerds, TA; Gislason, GH; Lamberts, M; Lip, GYH; Olesen, JB; Ozenne, B; Staerk, L; Torp-Pedersen, C | 1 |
| Agdirlioglu, T; Borowski, M; Kellner, M; Reers, S; Reppel, M; Thiele, H; Waltenberger, J | 1 |
| Al-Kahlili, F; Gilstring, Å; Haeggström, A; Risberg, D; Tullberg, U; Wallén, H | 1 |
| Ageno, W; Casella, IB; Desch, M; Goldhaber, SZ; Han, CK; Kimura, K; Raskob, GE; Schellong, S; Schulman, S; Singer, DE; Tang, W | 1 |
| Góralczyk, T; Malec, K; Undas, A | 1 |
| Buerke, M; Hoffmeister, HM | 1 |
| Weißbach, L; Zotz, RB | 1 |
| Ambrosino, P; Di Minno, A; Di Minno, G; Di Minno, MN; Tremoli, E | 1 |
| Attisani, M; Baronetto, A; Boffini, M; Centofanti, P; Ricci, D; Rinaldi, M; Simonato, E | 1 |
| Agnelli, G; Aita, A; Becattini, C; Conti, S; Giustozzi, M; Molini, G; Pierpaoli, L; Valecchi, F; Vedovati, MC; Verdecchia, P | 1 |
| Darius, H | 2 |
| Broscaru, L; Gulba, DC | 1 |
| Brand, S; Crespo, C; Kansal, A; Monreal-Bosch, M; Soulard, S | 1 |
| Burden, AM; de Boer, A; de Vries, F; Ebbelaar, C; Schalekamp, T; Souverein, P; Stolk, LM; Ten Cate-Hoek, A | 1 |
| Schulman, S | 1 |
| Dell'Aniello, S; Huiart, L; Loo, SY; Renoux, C | 1 |
| Bonde, AN; Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Olesen, JB; Sindet-Pedersen, C; Staerk, L | 1 |
| Andreas, M; Angleitner, P; Haberl, T; Laufer, G; Moayedifar, R; Riebandt, J; Schima, H; Schlöglhofer, T; Wiedemann, D; Wieselthaler, G; Wolzt, M; Zimpfer, D | 2 |
| Rogers, JG | 1 |
| Cifu, AS; Jain, A | 1 |
| Frossard, M; Koch, S; Pausch, A; Wiegele, M | 1 |
| Guenzer, JR; Meltzer, J | 1 |
| Abugattas de Torres, JP; Brugada, P; Chierchia, GB; Choudhury, R; Coutino-Moreno, HE; de Asmundis, C; De Regibus, V; Iacopino, S; Longobardi, M; Mugnai, G; Storti, C; Stroker, E; Takarada, K | 1 |
| Kemkes-Matthes, B | 1 |
| Gersh, BJ; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Ansell, J; Fonarow, GC; Gersh, BJ; Hylek, E; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Shrader, P; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Køber, L; Lamberts, M; Olesen, JB; Staerk, L; Vinding, NE | 1 |
| Jolobe, OMP | 1 |
| García-Sangenís, A; Giner-Soriano, M; Morros-Pedrós, R; Roso-Llorach, A; Vlacho, B; Zabaleta-Del-Olmo, E | 1 |
| Cossey, TC; Grotta, JC; Reddy, ST; Savitz, SI | 1 |
| Alla, F; Billionnet, C; Maura, G; Pariente, A | 1 |
| Jacobs, MS; Kappelhoff, B; Postma, MJ; Stevanovic, J; Tieleman, RG; van Hulst, M | 1 |
| Bellmann, B; Landmesser, U; Lenz, K; Lin, T; Lsharaf, AK; Nagel, P; Rillig, A; Roser, M; Tscholl, V | 1 |
| Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S | 1 |
| Collings, SL; Evans, D; Hack, G; Johnson, ME; Lefèvre, C; Maguire, A; Stynes, G | 1 |
| Alla, F; Billionnet, C; Gagne, JJ; Maura, G; Pariente, A | 1 |
| Heinrich-Nols, J; Kreuzer, J | 1 |
| Boulouis, G; Charidimou, A; Goldstein, JN; Gurol, ME; Morotti, A; Pasi, M | 1 |
| Abdul-Rahim, AH; Acampa, M; Acciarresi, M; Ageno, W; Agnelli, G; Alberti, A; Athanasakis, G; Bandini, F; Becattini, C; Bellesini, M; Bono, G; Bovi, P; Cappellari, M; Carletti, M; Carolei, A; Caso, V; Chiti, A; Chondrogianni, M; Ciccone, A; Cimini, LA; Colombo, G; Consoli, D; Corea, F; D'Amore, C; De Lodovici, ML; Denti, L; Falocci, N; Flomin, Y; Furie, KL; Galati, F; Gialdini, G; Giannini, N; Giorli, E; Giuntini, M; Gourbali, V; Guideri, F; Karagkiozi, E; Karapanayiotides, T; Kargiotis, O; Lanari, A; Lees, KR; Letteri, F; Liantinioti, C; Lorenzini, G; Lotti, EM; Maccarrone, M; Maimone Baronello, M; Makaritsis, K; Mancuso, M; Marcheselli, S; Martini, G; Masotti, L; Monaco, S; Mosconi, MG; Mumoli, N; Ntaios, G; Orlandi, G; Paciaroni, M; Padovani, A; Pezzini, A; Poli, L; Putaala, J; Sacco, S; Scoditti, U; Silvestrelli, G; Sohn, SI; Soloperto, R; Tadi, P; Tassi, R; Tassinari, T; Tatlisumak, T; Tiseo, C; Tomppo, L; Toni, D; Tsivgoulis, G; Vadikolias, K; Vannucchi, V; Venti, M; Yaghi, S; Zedde, M | 1 |
| D'Onofrio, A; Golino, P; Nigro, G; Papa, AA; Rago, A; Russo, V | 1 |
| Fuh, L; Goldstein, JN; Hayes, BD; Sin, JH | 1 |
| Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N | 1 |
| Escobar, C; Martí-Almor, J; Martínez-Zapata, MJ; Pérez Cabeza, A | 1 |
| Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L | 1 |
| Alves, JL; Fernandes, CJC; Gavilanes-Oleas, FA; Hoette, S; Jardim, C; Morinaga, L; Prada, LFL; Salibe Filho, W; Souza, R; Terra Filho, M | 1 |
| Cornelius, CC; Cripps, MW; Gales, PE; Nakonezny, PA; Vazquez, N; Wey, JC | 1 |
| Cavallari, I; De Caterina, R; Hanon, O; Patti, G | 1 |
| Basalo, MC; Ferrero-Martínez, AI; Gómez-Quintanilla, A; Guitián, A; Montero-Magan, M; Olcoz-Chiva, MT; Paredes-Galán, E; Rodríguez-Artalejo, F; Rodríguez-Pascual, C; Sharma, J; Torres-Torres, I; Vilches-Moraga, A | 1 |
| Grutters, JPC; Maas, AHEM; Rolden, HJA; van der Wilt, GJ | 1 |
| Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE | 1 |
| Mohebbi, N | 1 |
| Ferreira, M; Feuring, M; Fraessdorf, M; Huisman, MV; Klok, FA | 1 |
| Bowrin, K; Briere, JB; Coleman, C; Fauchier, L; Folkerts, K; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Abdulsattar, Y; Kamble, S; Lip, GYH; Mardekian, J; Masseria, C; Petkun, W; Phatak, H; Tepper, PG | 1 |
| Abouelfath, A; Bénichou, J; Blin, P; Cottin, Y; Droz, C; Dureau-Pournin, C; Lassalle, R; Mismetti, P; Moore, N | 2 |
| Campodonico, P; Guiddo, G; Lerza, R; Malerba, M; Minuto, P; Motta, G; Riccardi, A; Spinola, MB | 1 |
| Aisenberg, J; Elsaesser, A; Glund, S; Huisman, MV; Klok, FA; Lopes, RD; Pollack, CV; Reilly, P; Van der Wall, SJ; van Ryn, J | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Cheung, CY; Li, X | 1 |
| Ay, C; Beer, R; Haushofer, A; Kwasny, O; Leitgeb, J; Ortler, M; Schaden, E; Schöchl, H; Wiegele, M | 1 |
| Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, SR; Lee, YS; Park, HW; Park, J; Park, JK; Park, JS; Shim, J; Uhm, JS | 1 |
| Deitelzweig, S; Lip, GYH | 1 |
| Attena, E; Calabrò, P; Crisci, M; D'Onofrio, A; Golino, P; Nigro, G; Papa, AA; Proietti, R; Rago, A; Rainone, C; Russo, V | 1 |
| Basic, E; Hohnloser, SH; Nabauer, M | 1 |
| Baldus, S; Hohmann, C; Hohnloser, SH; Jacob, J; Pfister, R; Walker, J | 1 |
| Ferenci, T; Finta, E; Gasparics, R; Medvegy, M; Simonyi, G | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Imberti, D; Mastroiacovo, D; Pomero, F | 1 |
| Bowrin, K; Briere, JB; Coleman, CI; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Butt, JH; Fosbøl, EL; Garcia, D; Køber, L; Li, A; Peterson, ED; Torp-Pedersen, C; Xian, Y | 1 |
| Monreal, M; Morales-Indiano, C; Olive, A; Orna, E; Santos-Gómez, M; Sarrate, E; Sorigue, M | 1 |
| Gamanagatti, SR; Kumar, R; Rout, G; Sharma, S | 1 |
| Casajuana, M; Giner-Soriano, M; Morros, R; Roso-Llorach, A; Vedia, C | 1 |
| Beauchesne, LM; Bouma, BJ; Khairy, P; Macle, L; Mongeon, FP; Mulder, BJM; Schwerzmann, M | 1 |
| Bernard, MA; Blin, P; Dallongeville, J; Droz-Perroteau, C; Dureau-Pournin, C; Fauchier, L; Lassalle, R; Moore, N; Sacher, F | 1 |
| Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK | 1 |
| Bonde, AN; Fosbøl, EL; Gislason, GH; Køber, L; Lee, CJ; Olesen, JB; Rørth, R; Staerk, L; Torp-Pedersen, C; Vinding, NE | 1 |
| Adabala, N; Bommana, S; Di Biase, L; Gianni, C; Gopinathannair, R; Khalafi, M; Lakkireddy, D; Lakkireddy, P; Maybrook, R; Mohanty, S; Natale, A; Parikh, V; Pillarisetti, J; Reddy, MY; Reddy, S; Saksena, S | 1 |
| Lip, GYH; Mujovic, N; Potpara, TS | 1 |
| Chao, HC; Jeng, JS; Jhang, RS; Kuo, CH; Liao, HW; Lin, SY; Lin, YT; Peng, YF; Tang, SC; Tsai, IL | 1 |
| Boissier, E; Bourcier, R; Dargazanli, C; Desal, H; Gory, B; Kyheng, M; L'Allinec, V; Labreuche, J; Lapergue, B; Mazighi, M; Roy, M; Sibon, I | 1 |
| Ali, H; Hanley, DF; Marsh, EB; Nyquist, PA; Shin, SS; Ziai, WC | 1 |
| Chen, N; Holbrook, A; Lee, M; Leenus, A; Liu, J; Mbuagbaw, L; Thabane, L; Wang, M | 1 |
| Albrecht, H; Hagel, AF; Konturek, PC; Maass, LS; Neurath, MF; Raithel, M | 1 |
| Fosbøl, EL; Køber, L; Vinding, NE | 1 |
| Heinrich-Nols, J; van Ryn, J | 1 |
| Benczur, B; Bergler-Klein, J; Ciernik, M; Gotcheva, N; Medvedchikov, A; Napalkov, D; Põder, P; Simic, D; Skride, A; Tang, W; Trusz-Gluza, M; Vesely, J; Vinereanu, D; Vishnepolsky, T; Vrabec, M | 1 |
| Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S | 1 |
| Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG | 1 |
| Ashley, J; Badve, SV; Battistella, M; Bota, S; Garg, AX; Harel, Z; Jun, M; Manuel, D; Mavrakanas, T; McArthur, E; Molnar, AO; Rhodes, E; Sood, MM; Tanuseputro, P; Wells, P | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A | 1 |
| Balusson, F; Bouget, J; Lacut, K; Maignan, M; Nowak, E; Oger, E; Pavageau, L; Roy, PM; Scailteux, LM | 1 |
| Chaudhary, R; Garg, J; McBane, RD; Murad, MH; Pagali, S; Wysokinski, WE | 1 |
| Arellano-Rodrigo, E; Barrios, V; Donado, E; Escobar, C; Fernández-Dueñas, J; Garrido, RR; Gómez-Doblas, JJ; Rodríguez, JP; Sánchez, JU | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Pazan, F; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, AL; Keshishian, AV; Li, X; Lip, GYH; Luo, X; Mardekian, J; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Aakjaer, M; Andersen, M; De Bruin, ML; Gardarsdottir, H; Heeke, A; Huerta, C; Klungel, OH; León-Muñoz, LM; Merino, EM; Montero, D; Rottenkolber, M; Schmiedl, S; Souverein, PC; van den Ham, HA | 1 |
| Fanning, L; Lau, WCY; Man, KKC; Mongkhon, P; Wong, ICK; Wong, KHTW | 1 |
| Chern, AKC; Choi, EK; Chutinet, A; Hanafy, DA; Jiampo, P; Lee, YS; Oh, YS; Trivedi, P; Zhai, D | 2 |
| Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
| Lee, EM; Tan, VH; Tan, YC; Tiew, WJ; Wong, VL | 1 |
| Lorenzoni, V; Pirri, S; Turchetti, G | 1 |
| Luna, JD; Manzano-Gamero, V; Pardo-Cabello, AJ | 1 |
| Bauwens, M; Brandenburg, V; Briedé, JJ; Bröker, V; Bucerius, J; Dijkgraaf, I; Dweck, MR; Jennen, D; Leenders, P; Mottaghy, F; Reutelingsperger, CP; Schurgers, LJ; Spronk, HMH; van Gorp, RH; van Ryn, J | 1 |
| Benczur, B; Bergler-Klein, J; Ciernik, M; Gotcheva, N; Medvedchikov, A; Napalkov, D; Põder, P; Simić, D; Skride, A; Tang, W; Trusz-Gluza, M; Vesely, J; Vinereanu, D | 1 |
| Anoopkumar-Dukie, S; Badrick, T; Bernaitis, N | 1 |
| Buenen, AG; Maas, ML; Sinkeldam, M; Verdonschot, M; Wever, PC | 1 |
| Benamouzig, R; Deutsch, D; Fauchier, L; Guenoun, M | 1 |
| Abenhaim, L; Benichou, J; Davy, JM; Dialla, O; Ferrières, J; Grimaldi-Bensouda, L; Le Heuzey, JY; Leys, D; Martinez, M; Nighoghossian, N; Nordon, C; Smadja, D; Touzé, E | 1 |
| Chen, J; Chen, M; Fang, Z; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 1 |
| Attia, J; Bagepally, BS; Chaikledkaew, U; Chaiyakunapruk, N; McKay, G; Nathisuwan, S; Noviyani, R; Sritara, P; Thakkinstian, A; Youngkong, S | 1 |
| Amin, AN; Auladell-Rispau, A; Barrios, V; Escobar, C; Lip, GYH; Requeijo, C; Salazar, J; Santero, M | 1 |
| Albisetti, M; Brandão, LR; Male, C; Monagle, P; Young, G | 1 |
| Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L | 1 |
| Huang, CF; Huang, TM; Jeng, JS; Kuo, CH; Lin, SY; Peng, YF; Tang, SC | 1 |
| Nalezinski, S | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; Gurusamy, VK; Halperin, JL; Huisman, MV; Lip, GYH; Lohmann, R; Lu, S; Ma, CS; Rothman, KJ; Teutsch, C | 1 |
| da Silva, RMFL | 1 |
| Bowrin, K; Briere, JB; Cabeza, AIP; Escobar Cervantes, C; Gasche, D; Genís Gironès, M; Llorac Moix, A; Martí-Almor, J; Millier, A; Tardu, J; Toumi, M | 1 |
| Aigner, E; Balcar, L; Bartl, S; Datz, C; Gensluckner, S; Hametner-Schreil, S; Hofer, H; Lampichler, K; Lindorfer, A; Mandorfer, M; Pomej, K; Reiberger, T; Schäfer, B; Scheiner, B; Schöfl, R; Semmler, G; Trauner, M; Zoller, H | 1 |
| Alkhameys, S; Barrett, R | 1 |
| Chandrasegaram, A; Peters, CD | 1 |
| Archontakis-Barakakis, P; Batsidis, A; Giamouzis, G; Giannakoulas, G; Giannopoulos, S; Kalaitzoglou, D; Kokkinidis, DG; Li, W; Lip, GYH; Manolopoulos, A; Ntaios, G; Palaiodimos, L; Tzelves, L | 1 |
| Cao, S; He, T; Wu, X; Yu, B | 1 |
| Abbasi, G; Daei, M; Heidari, Z; Khalili, H | 1 |
| Anguita, M; Badimón, L; Bertomeu-Martínez, V; Cequier, Á; Esteve-Pastor, MA; Lip, GYH; López-Gálvez, R; Marín, F; Muñiz, J; Otero, D; Rivera-Caravaca, JM; Roldán-Rabadán, I; Ruiz-Ortiz, M | 1 |
| Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P | 1 |
| Amico, F; Colivicchi, F; Di Fusco, SA; Giubilato, S; Gulizia, MM; Lucà, F | 1 |
| Bloom, B; Cohen-Aubart, F; Freund, Y | 1 |
| Baker, L; Bartels, DB; Beier, L; Diener, HC; Dubner, SJ; França, LR; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Lyrer, P; Ma, CS; Marler, S; Paquette, M; Rothman, KJ; Senges, J; Teutsch, C; Zint, K | 1 |
| Gosselin, L; Lévy, C; Steichen, O; Vilcu, AM | 1 |
| Bortman, LV; Di Girolamo, G; Giorgi, MA; Gonzalez, CD; Mitchell, F; Naveiro, S; Pérez Morales, J | 1 |
| Altın, C; Aslan, O; Bilgel, ZG; Boyraz, B; Çakal, S; Çayırlı, S; Çoner, A; Coşgun, MS; Dal, A; Dalgıç, O; Demir, M; Doğduş, M; Erdoğan, A; Ergin, I; Genç, Ö; Güler, A; Güvendi Şengör, B; İbişoğlu, E; İlkay Yüce, E; Kaplan, M; Karabulut, D; Karabulut, U; Keskin Meriç, B; Kıvrak, T; Kocabaş, U; Murat, B; Murat, S; Naki Tekin, DD; Özçalık, E; Özdemir, I; Özgeyik, M; Özyurtlu, F; Şahin, Ş; Şen, T; Tüner, H; Urgun, ÖD; Uzman, O; Yavuz, V | 1 |
| De Caterina, R; van Es, N; Weitz, JI | 1 |
| Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
| Chen, J; Ma, F; Xu, W; Zhang, J | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Chang, YM; Chen, CH; Hsieh, MT; Lin, PY; Lin, SH; Liu, CH; Sung, PS; Wang, CM | 1 |
122 review(s) available for dabigatran and vitamin k semiquinone radical
| Article | Year |
|---|---|
Oral direct thrombin inhibitors in clinical development.
Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
New anticoagulants: from bench to bedside.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Polysaccharides; Pyridines; Thrombin; Vitamin K | 2007 |
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Prothrombin; Pyridines; Risk Assessment; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2009 |
New anticoagulants for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K | 2009 |
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Drug Therapy, Combination; Humans; Pyridines; Risk Factors; Stroke; Survival Rate; Thrombin; Vitamin K | 2010 |
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzimidazoles; Benzylamines; Contraindications; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2010 |
New oral anticoagulant drugs in cardiovascular disease.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Pyridines; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
[New oral anticoagulants: better than vitamin K antagonists?].
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K | 2010 |
Managing bleeding complications in patients treated with the old and the new anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Polysaccharides; Protamines; Recombinant Proteins; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Health Status Indicators; Humans; Risk Assessment; Stroke; Vitamin K; Warfarin | 2011 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2011 |
Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Interactions; Heparinoids; Humans; Pulmonary Embolism; Pyridines; Stroke; Venous Thromboembolism; Vitamin K | 2011 |
Characteristics of novel anticoagulants and potential economic implications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; Medication Adherence; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Vitamin K | 2011 |
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Fondaparinux; Heart Valve Prosthesis Implantation; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
[New anticoagulants. Characteristics, monitoring and management of bleeding].
Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2011 |
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Perioperative Care; Stroke; Thromboembolism; Vitamin K | 2011 |
Stroke prevention in atrial fibrillation: do we still need warfarin?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Decision Making; Factor Xa Inhibitors; Humans; Risk Factors; Stroke; Thrombin; Vitamin K; Warfarin | 2012 |
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombosis; United States; Vitamin K | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Acute stroke management in patients taking dabigatran.
Topics: Anticoagulants; Benzimidazoles; Blood Coagulation Disorders; Case Management; Cerebral Hemorrhage; Cerebral Infarction; Dabigatran; Guidelines as Topic; Hemostasis; Hemostatics; Humans; Off-Label Use; Pyridines; Renal Dialysis; Reperfusion; Stroke; Vitamin K | 2012 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fibrinolytic Agents; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Intracranial Embolism; Multicenter Studies as Topic; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Single-Blind Method; Thrombophilia; Vitamin K | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
Anticoagulant therapy: basic principles, classic approaches and recent developments.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudins; Humans; Platelet Aggregation Inhibitors; Thrombin; Thromboembolism; Thrombophilia; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Monitoring, Ambulatory; Self Care; Stroke; Thromboembolism; Vitamin K; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K | 2012 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2013 |
[From heparin to apixaban: anticoagulants cut both ways?].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; International Normalized Ratio; Liver Failure; Metabolic Clearance Rate; Morpholines; Perioperative Care; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Vitamin K | 2014 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; Biotin; Dabigatran; Humans; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Thiazoles; Venous Thromboembolism; Vitamin K | 2013 |
Managing blunt trauma in patients receiving dabigatran etexilate: case study and review of the literature.
Topics: Accidental Falls; Aged; Benzimidazoles; Dabigatran; Dementia; Female; Hemorrhage; Humans; Pneumothorax; Pyridines; Rib Fractures; Spleen; Thoracostomy; Vitamin K; Wounds, Nonpenetrating | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
[New clinical perspectives in the management of oral direct anticoagulant agents].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2014 |
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Intracranial Hemorrhages; Pyridines; Risk Assessment; Risk Factors; Stroke; Vitamin K | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[Gastrointestinal bleeding in cardiological patients].
Topics: Algorithms; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Metabolic Clearance Rate; Morpholines; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Transfusion; Rivaroxaban; Thiophenes; Vitamin K | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Vitamin K | 2014 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism; Vitamin K; Warfarin | 2014 |
[Monitoring options and reversal agents for oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Renal Insufficiency, Chronic; Venous Thromboembolism; Vitamin K | 2015 |
Reversal of anticoagulants: an overview of current developments.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzamides; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostatics; Heparin; Humans; Infusions, Parenteral; Intracranial Hemorrhages; Polysaccharides; Protamines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombosis; Vitamin K | 2015 |
Management of anticoagulation in patients with acute gastrointestinal bleeding.
Topics: Acenocoumarol; Acute Disease; Algorithms; Anticoagulants; Coagulants; Dabigatran; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Vitamin K; Warfarin | 2015 |
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism; Vitamin K | 2015 |
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Comorbidity; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Risk Factors; Sex Factors; Stroke; Vitamin K | 2015 |
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Venous Thromboembolism; Vitamin K | 2015 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
[Treatment of bleeding complications due to oral anticoagulant drugs].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2015 |
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Vitamin K | 2016 |
Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Vitamin K | 2016 |
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Prothrombin; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Arginine; Blood Coagulation Disorders; Blood Coagulation Factors; Coagulants; Combined Modality Therapy; Dabigatran; Drugs, Investigational; Enoxaparin; Factor Xa; Fibrinolytic Agents; Humans; Piperazines; Practice Guidelines as Topic; Recombinant Proteins; Vitamin K | 2016 |
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drugs, Investigational; Evidence-Based Medicine; Humans; Mexico; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2016 |
Why switch from warfarin to NOACs?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Survival Rate; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Causality; Comorbidity; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thromboembolism; Treatment Outcome; Vitamin K | 2016 |
Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Observational Studies as Topic; Stroke; Vitamin K | 2016 |
Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Myocardial Infarction; Observational Studies as Topic; Risk Assessment; Vitamin K | 2016 |
[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Loss, Surgical; Dabigatran; Drug Interactions; Half-Life; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiazoles; Thromboembolism; Vitamin K | 2017 |
The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Vitamin K | 2017 |
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2017 |
Bleeding Complications and Management on anticoagulant therapy.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Vitamin K | 2017 |
Anticoagulant Reversal and Anesthetic Considerations.
Topics: Anesthetics; Anticoagulants; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Factor VIIa; Factor Xa Inhibitors; Hemorrhage; Humans; Protamines; Vitamin K | 2017 |
[Anticoagulation-direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Biological Availability; Body Weight; Dabigatran; Humans; Thromboembolism; Vitamin K | 2017 |
Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Factor Xa; Hemorrhage; Humans; Recombinant Proteins; Stroke; Thrombolytic Therapy; Vitamin K | 2017 |
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thrombosis; Vitamin K | 2017 |
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Hematoma; Humans; Mortality; Odds Ratio; Phenprocoumon; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Thiazoles; Vitamin K; Warfarin | 2018 |
Reversal of Oral Anticoagulants for Intracerebral Hemorrhage Patients: Best Strategies.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Humans; Vitamin K | 2017 |
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Case-Control Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2019 |
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Rivaroxaban; Treatment Outcome; Vitamin K | 2018 |
THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Cost-Benefit Analysis; Dabigatran; Decision Making; Female; Humans; Male; Models, Economic; Quality-Adjusted Life Years; Stroke; Surveys and Questionnaires; United States; Vitamin K | 2018 |
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K | 2018 |
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2018 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2020 |
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Vitamin K | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke; Survival Analysis; Thiazoles; Vitamin K | 2019 |
Barriers and facilitators to optimal oral anticoagulant management: a scoping review.
Topics: Anticoagulants; Dabigatran; Disease Management; Factor Xa Inhibitors; Humans; Quality of Health Care; Rivaroxaban; Thromboembolism; Vitamin K; Warfarin | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Vitamin K | 2020 |
A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Consensus Development Conferences as Topic; Dabigatran; Europe; Female; Humans; Long-Term Care; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2021 |
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Italy; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2021 |
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Vitamin K | 2022 |
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Humans; Stroke; Vitamin K | 2022 |
Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2021 |
Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review.
Topics: Anticoagulants; Blood Coagulation Disorders; Dabigatran; Emergencies; Hemorrhage; Humans; Vitamin K | 2022 |
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2022 |
The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Rivaroxaban; Stroke; Vitamin K | 2022 |
Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Intracranial Hemorrhages; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2022 |
Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Thrombosis; Venous Thromboembolism; Vitamin K | 2022 |
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2022 |
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Mass Index; Body Weight; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2022 |
Acute Pulmonary Embolism: A Review.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dabigatran; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Pulmonary Embolism; Risk; Rivaroxaban; United States; Vitamin K; Warfarin | 2022 |
Use of tramadol and the risk of bleeding complications in patients on oral anticoagulants: a systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Tramadol; Vitamin K | 2022 |
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pharmacology, Clinical; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2023 |
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Pyridones; Rheumatic Heart Disease; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2023 |
9 trial(s) available for dabigatran and vitamin k semiquinone radical
| Article | Year |
|---|---|
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyridines; Risk Factors; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2010 |
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Follow-Up Studies; Humans; Prospective Studies; Pyridines; Risk Factors; Stroke; Vitamin K; Warfarin | 2011 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 Enzyme System; Dabigatran; Double-Blind Method; Electrodes; Female; Humans; Light; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Thrombelastography; Thrombosis; Ticlopidine; Vitamin K | 2016 |
Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Atrial Function, Left; Dabigatran; Electrocardiography; Female; Heart Atria; Humans; Male; Middle Aged; Rivaroxaban; Thrombosis; Vitamin K | 2016 |
Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial.
Topics: Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Equipment Failure; Female; Follow-Up Studies; Heart Ventricles; Heart-Assist Devices; Humans; Male; Middle Aged; Phenprocoumon; Pilot Projects; Prospective Studies; Thromboembolism; Time Factors; United States; Vitamin K | 2017 |
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2017 |
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Body Mass Index; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obesity; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists.
Topics: Aged; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Reperfusion; Rivaroxaban; Stroke; Thrombectomy; Treatment Outcome; Vitamin K | 2020 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
155 other study(ies) available for dabigatran and vitamin k semiquinone radical
| Article | Year |
|---|---|
[Anticoagulation in atrial fibrillation].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Humans; Middle Aged; Pyridines; Risk Factors; Stroke; Vitamin K | 2008 |
The novel anticoagulants: entering a new era.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombolytic Therapy; Vitamin K | 2009 |
Dabigatran: new drug. Continue to use heparin, a better-known option.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Drug Approval; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; France; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Vitamin K | 2009 |
[Anticoagulation in atrial fibrillation. Stroke can be prevented this way].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; International Normalized Ratio; Intracranial Embolism; Pyridines; Stroke; Vitamin K | 2009 |
[Stroke prevention in atrial fibrillation. Marcumar alternative in sight].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Phenprocoumon; Pyridines; Randomized Controlled Trials as Topic; Stroke; Vitamin K | 2009 |
When a virtue becomes a problem. The new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Medication Adherence; Risk; Vitamin K; Warfarin | 2010 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Diagnosis, Differential; Dronedarone; Humans; Vitamin K | 2010 |
Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
Topics: Administration, Oral; Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Vitamin K; Warfarin | 2010 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Risk Assessment; Stroke; Vitamin K | 2011 |
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
[Is the era from the end of warfarin?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Countershock; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Risk Factors; Societies, Medical; Stroke; Ticlopidine; Vitamin K | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin | 2012 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
Topics: Aged; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Quality of Life; Quality-Adjusted Life Years; Stroke; Switzerland; Vitamin K | 2013 |
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran].
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Electric Countershock; Humans; Ileus; Kidney Diseases; Male; Risk Factors; Thromboembolism; Tomography, X-Ray Computed; Vitamin K | 2013 |
Antidotes edge closer to reversing effects of new blood thinners.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Humans; Pyrazoles; Pyridones; Recombinant Proteins; Vitamin K; Warfarin | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[Prevention and treatment of major bleeding during anticoagulation].
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Diabetes Mellitus; Drug Therapy, Combination; Factor IX; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Risk Assessment; Risk Factors; Smoking; Vitamin K; Warfarin | 2013 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Substitution; Early Termination of Clinical Trials; Female; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Middle Aged; Mitral Valve; Myocardial Infarction; Off-Label Use; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Vitamin K | 2014 |
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Registries; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Middle Aged; Quality of Life; Ventricular Dysfunction, Left; Vitamin K | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lopinavir; Male; Middle Aged; Protease Inhibitors; Pyridines; Ritonavir; Treatment Outcome; Vitamin K | 2014 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K | 2015 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Dipeptides; Enzyme Assays; Factor Xa Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Whole Blood Coagulation Time | 2015 |
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Prevalence; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2015 |
Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Monitoring; Humans; International Normalized Ratio; Mass Spectrometry; Partial Thromboplastin Time; Prothrombin Time; Retrospective Studies; Rivaroxaban; ROC Curve; Sensitivity and Specificity; Thromboembolism; Time Factors; Vitamin K | 2015 |
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.
Topics: Administration, Oral; Anticoagulants; Chromatography, Liquid; Dabigatran; Humans; Pyrazoles; Pyridones; Quality Control; Rivaroxaban; Tandem Mass Spectrometry; Vitamin K | 2015 |
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Middle Aged; Risk; Rivaroxaban; Thromboembolism; Thrombophilia; Vitamin K; Warfarin; Young Adult | 2015 |
Extreme warfarin hypersensitivity after oophorectomy.
Topics: Anticoagulants; Blood Coagulation Factors; Dabigatran; Drug Hypersensitivity; Drug Substitution; Female; Heparin; Humans; International Normalized Ratio; Middle Aged; Ovariectomy; Venous Thromboembolism; Vitamin K; Warfarin | 2015 |
Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Fibrinolytic Agents; Hemorrhage; Humans; Male; Markov Chains; Quality-Adjusted Life Years; Self Care; Stroke; Thrombosis; Vitamin K; Warfarin | 2015 |
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Registries; Stroke; Treatment Outcome; Vitamin K | 2015 |
Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function.
Topics: Animals; Anticoagulants; Antithrombins; Aorta; Bone and Bones; Bone Diseases, Metabolic; Bone Remodeling; Calcinosis; Dabigatran; Female; Fractures, Spontaneous; Iliac Artery; Kidney; Minerals; Osteoblasts; Osteoclasts; Random Allocation; Rats; Rats, Sprague-Dawley; Vascular Diseases; Vitamin K; Warfarin | 2015 |
Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
Topics: Anticoagulants; Antithrombins; Cost Savings; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Health Resources; Humans; Netherlands; Pulmonary Embolism; Quality-Adjusted Life Years; Retrospective Studies; Venous Thrombosis; Vitamin K | 2015 |
Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Area Under Curve; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Blood Platelets; Calibration; Dabigatran; Femoral Fractures; Fibrin Fibrinogen Degradation Products; Hemodynamics; Hemorrhage; Hemostasis; Male; Multiple Trauma; Partial Thromboplastin Time; Platelet Aggregation; Platelet Function Tests; Prothrombin Time; Random Allocation; Swine; Thrombelastography; Thrombin; Time Factors; Vitamin K | 2016 |
Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
Topics: Administration, Oral; Aged; Anticoagulants; Area Under Curve; Atrial Fibrillation; Brain Ischemia; Computer Simulation; Dabigatran; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Stroke; Vitamin K | 2016 |
Oral anticoagulant therapy and thrombosis. A case of failure of therapy with vitamin K antagonists.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dyspnea; Echocardiography; Humans; Male; Radiography; Thrombosis; Tomography Scanners, X-Ray Computed; Treatment Failure; Vitamin K | 2016 |
[Appropriateness of the prescriptions of conventional versus new oral anticoagulants at discharge from a department of internal medicine].
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Middle Aged; Patient Discharge; Phenprocoumon; Retrospective Studies; Rivaroxaban; Vitamin K | 2016 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Phenindione; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2015 |
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharm
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Consensus; Dabigatran; Evidence-Based Medicine; Factor Xa; Forecasting; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Thrombosis; Vitamin K | 2017 |
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2016 |
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Follow-Up Studies; Germany; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Retrospective Studies; Risk Reduction Behavior; Rivaroxaban; Stroke; Vitamin K | 2016 |
Management of bleeding complications in patients with cancer on DOACs.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Italy; Logistic Models; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Vitamin K | 2016 |
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiac Surgical Procedures; Dabigatran; Emergencies; Female; Gastrointestinal Hemorrhage; Heart Transplantation; Hemorrhage; Hemostatics; Heparin; Humans; Incidence; International Normalized Ratio; Intracranial Hemorrhages; Laparotomy; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Thrombocytopenia; Thromboembolism; Vitamin K; Warfarin | 2016 |
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Denmark; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Registries; Stroke; Vitamin K | 2016 |
Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Warfarin | 2016 |
"Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Vitamin K | 2016 |
[Safer treatment with serum concentration monitoring of the new anticoagulants?].
Topics: Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Pyrazoles; Pyridones; Reference Standards; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Denmark; Female; Hospitalization; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
[Gastrointestinal bleeding during treatment with nonvitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Pilot Projects; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pulmonary Embolism; Research Design; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Vitamin K; Young Adult | 2017 |
[Monitoring of NOAC].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Emergency Service, Hospital; Hemorrhage; Humans; Intensive Care Units; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Dabigatran etexilate in a vitamin-K antagonist non responder patient during Heartware HVAD support.
Topics: Aged; Antithrombins; Cardiomyopathy, Dilated; Dabigatran; Female; Follow-Up Studies; Heart-Assist Devices; Humans; Postoperative Care; Thrombosis; Vitamin K | 2017 |
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2017 |
[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Electric Countershock; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Intensive Care Units; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin; Thromboembolism; Vitamin K | 2017 |
[Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Markov Chains; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2017 |
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Vitamin K | 2017 |
Trends in the prescription of novel oral anticoagulants in UK primary care.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; United Kingdom; Vitamin K | 2017 |
Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Balancing Bleeding and Clotting: The Known Unknowns of Mechanically Assisted Circulation.
Topics: Dabigatran; Heart-Assist Devices; Hemorrhage; Humans; Pilot Projects; Vitamin K | 2017 |
Antithrombotic Therapy for Venous Thromboembolic Disease.
Topics: Antithrombins; Dabigatran; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Review Literature as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
The diagnostic challenge of a vitamin K antagonist with dabigatran use triggering massive intracranial haemorrhage.
Topics: Aged, 80 and over; Anticoagulants; Dabigatran; Dementia; Drug Overdose; Fatal Outcome; Humans; Intracranial Hemorrhages; Male; Multiple Organ Failure; Skull Fractures; Vitamin K | 2017 |
Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Topics: Ablation Techniques; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Belgium; Cryosurgery; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Intraoperative Period; Italy; Male; Middle Aged; Postoperative Complications; Prognosis; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thiazoles; Time Factors; Vitamin K | 2017 |
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Vitamin K; Young Adult | 2017 |
Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Substitution; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2018 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2017 |
Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Topics: Aged; Antithrombins; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Electronic Health Records; Female; Humans; Logistic Models; Male; Treatment Outcome; Vitamin K | 2017 |
Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comorbidity; Dabigatran; Databases, Factual; Female; France; Health Care Surveys; Humans; Male; Medication Adherence; Middle Aged; Myocardial Ischemia; Rivaroxaban; Stroke; Vitamin K | 2017 |
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
Topics: Antithrombins; Atrial Fibrillation; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Markov Chains; Netherlands; Quality-Adjusted Life Years; Retrospective Studies; Risk Assessment; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Cardiac Catheters; Cerebrovascular Disorders; Cryosurgery; Dabigatran; Drug Administration Schedule; Drug Monitoring; Equipment Design; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; France; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Medication Adherence; Middle Aged; Rivaroxaban; Stroke; Vitamin K | 2018 |
Letter by Heinrich-Nols and Kreuzer Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial".
Topics: Anticoagulants; Dabigatran; Heart-Assist Devices; Humans; Pilot Projects; Thromboembolism; Vitamin K | 2017 |
Response by Andreas et al to Letter Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial".
Topics: Anticoagulants; Dabigatran; Heart-Assist Devices; Humans; Pilot Projects; Thromboembolism; Vitamin K | 2017 |
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
Topics: Adult; Aged; Atrial Fibrillation; Cohort Studies; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Prospective Studies; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Angiography; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Incidence; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Patient Safety; Phenindione; Propensity Score; Proportional Hazards Models; Risk; Treatment Outcome; Vitamin K | 2018 |
Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antithrombins; Chronic Disease; Dabigatran; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Reproducibility of Results; Treatment Outcome; Vitamin K | 2018 |
In vitro effects of a kaolin-coated hemostatic dressing on anticoagulated blood.
Topics: Adult; Anticoagulants; Antithrombins; Arginine; Bandages; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemostatics; Heparin; Humans; Kaolin; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban; Sulfonamides; Viscoelastic Substances; Vitamin K | 2018 |
Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Dementia; Dicumarol; Disabled Persons; Follow-Up Studies; Hemorrhage; Humans; Mobility Limitation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2018 |
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Topics: Adolescent; Adult; Anticoagulants; Clinical Trials as Topic; Contraceptives, Oral, Hormonal; Dabigatran; Factor Xa Inhibitors; Female; Humans; Incidence; Menorrhagia; Middle Aged; Multicenter Studies as Topic; Uterine Hemorrhage; Venous Thromboembolism; Vitamin K; Warfarin; Young Adult | 2018 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2019 |
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Inpatients; Male; Middle Aged; Outpatients; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2018 |
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; Vitamin K | 2019 |
Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Craniocerebral Trauma; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2019 |
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Risk Assessment; United States; Venous Thromboembolism; Vitamin K | 2019 |
Dabigatran causing severe acute kidney injury in a patient with liver cirrhosis.
Topics: Acute Kidney Injury; Administration, Intravenous; Antifibrinolytic Agents; Antithrombins; Dabigatran; Humans; Kidney Tubules; Liver Cirrhosis; Male; Middle Aged; Necrosis; Severity of Illness Index; Treatment Outcome; Vitamin K | 2019 |
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.
Topics: Administration, Oral; Anticoagulants; Austria; Brain Injuries, Traumatic; Consensus; Dabigatran; Deamino Arginine Vasopressin; Humans; Interdisciplinary Communication; Partial Thromboplastin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Tomography, X-Ray Computed; Tranexamic Acid; Treatment Outcome; Vitamin K | 2019 |
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Drug Labeling; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Risk Factors; Rivaroxaban; Thiazoles; Vitamin K | 2019 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review.
Topics: Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2019 |
Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
Topics: Aged; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Pilot Projects; Probability; Propensity Score; Thromboembolism; Treatment Outcome; Vitamin K | 2019 |
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Withholding Treatment | 2019 |
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Geriatrics; Germany; Humans; Middle Aged; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K | 2019 |
[One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Humans; Hungary; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Vitamin K | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Data Systems; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Male; Propensity Score; Rivaroxaban; Vitamin K | 2020 |
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Denmark; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Pyrazoles; Pyridones; Rivaroxaban; United States; Vitamin K; Warfarin | 2019 |
Dabigatran for catastrophic antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Catastrophic Illness; Dabigatran; Factor Xa Inhibitors; Humans; Male; Treatment Outcome; Vitamin K | 2019 |
Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.
Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Dabigatran; Endovascular Procedures; Female; Follow-Up Studies; Humans; Male; Retrospective Studies; Stents; Vitamin K; Young Adult | 2020 |
[Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Primary Health Care; Propensity Score; Stroke; Thromboembolism; Vitamin K | 2020 |
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2020 |
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2020 |
Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Vitamin K | 2021 |
Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Defibrillators, Implantable; Female; Humans; Male; Middle Aged; Pyridones; Rivaroxaban; Vitamin K; Warfarin | 2020 |
Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Prejudice; Rivaroxaban; Stroke; Vitamin K | 2020 |
Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots.
Topics: Administration, Oral; Anticoagulants; Blood Volume; Chromatography, Liquid; Dabigatran; Dried Blood Spot Testing; Humans; Pyrazoles; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Vitamin K | 2020 |
Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Glasgow Outcome Scale; Humans; Intracranial Hemorrhage, Traumatic; Length of Stay; Male; Middle Aged; Mortality; Neurosurgical Procedures; Plasma; Platelet Transfusion; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Vitamin K; Warfarin | 2020 |
Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K; Young Adult | 2019 |
Comment on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Vitamin K | 2021 |
Comments on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Vitamin K | 2021 |
Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Europe; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Israel; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Protective Factors; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vitamin K; Young Adult | 2020 |
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Antithrombins; Brain Ischemia; Cause of Death; Comorbidity; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Myocardial Revascularization; Ontario; Procedures and Techniques Utilization; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Thrombophilia; Vitamin K | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Stroke; Vitamin K | 2020 |
Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Perception; Prospective Studies; Stroke; Vitamin K | 2020 |
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Frail Elderly; Hemorrhage; Humans; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Vitamin K; Warfarin | 2021 |
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Male; Rivaroxaban; Spain; Stroke; Vitamin K | 2021 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Asia; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Stroke; Time Factors; Treatment Outcome; Vitamin K | 2020 |
A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Singapore; Stroke; Vitamin K; Warfarin; Young Adult | 2020 |
Comparative study of adverse drug reactions among direct-acting oral anticoagulants and vitamin K antagonists using the EudraVigilance database.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Young Adult | 2021 |
Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate.
Topics: Animals; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Female; Humans; Mice; Vitamin K; Warfarin | 2021 |
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Middle Aged; Prospective Studies; Stroke; Vitamin K | 2021 |
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2021 |
Prior use of anticoagulation is associated with a better survival in COVID-19.
Topics: Administration, Oral; Anticoagulants; COVID-19; Dabigatran; Fibrinolytic Agents; Humans; Netherlands; Survival Rate; Vitamin K | 2021 |
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Female; Heart Disease Risk Factors; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; Risk Factors; Stroke; Treatment Outcome; Vitamin K | 2021 |
Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children.
Topics: Anticoagulants; Child; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Risk Factors; Rivaroxaban; Venous Thromboembolism; Vitamin K | 2022 |
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2022 |
Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia, Southeastern; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Male; Patient Satisfaction; Perception; Prevalence; Republic of Korea; Retrospective Studies; Risk Management; Stroke; Time Factors; Vitamin K | 2021 |
Impact of different renal function equations on direct oral anticoagulant concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Creatinine; Cystatin C; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2021 |
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Prospective Studies; Registries; Stroke; Vitamin K | 2022 |
Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Mitral Valve Stenosis; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Austria; Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Dabigatran; End Stage Liver Disease; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Retrospective Studies; Severity of Illness Index; Vitamin K | 2023 |
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; England; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Interrupted Time Series Analysis; Pandemics; Prescriptions; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Direct oral anticoagulants toxicity in children: an overview and practical guide.
Topics: Administration, Oral; Anticoagulants; Charcoal; Child; Dabigatran; Hemorrhage; Hemostatics; Humans; Vitamin K | 2022 |
[Reversal agents for severe bleeding associated with direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Rivaroxaban; Vitamin K | 2022 |
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Registries; Stroke; Vitamin K | 2022 |
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Vitamin K; Young Adult | 2023 |
Reversal agents for current and forthcoming direct oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Rivaroxaban; Vitamin K | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Stroke; Subarachnoid Hemorrhage; Vitamin K; Warfarin | 2023 |